AQSZF
OQB Aequus Pharmaceuticals, Inc.$0.0002 ↓ -0.0003 (-60.00%) Trading Down from the previous close of $0.0005, and at the day’s high of $0.0002
- YTD change
- -71.43%
- vs 20-day SMA
- N/A
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-0.00 (-60.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.5% away from all-time highs of $0.0080
- AQSZF is down 71% since the beginning of the year
- AQSZF is down 71% over the past 12 months
- AQSZF is down 71% over the past 1 month
AQSZF reads n/a: the 12-month move is -81.8%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -71.43%
- vs 8-day SMA
- N/A
No alerts for AQSZF in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its product include, Tacrolimus IR, which are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, Alexander Goumeniouk, Douglas Glen Janzen and Anne Michelle Stevens on January 3, 2013 and is headquartered in Vancouver, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
